Q3 Earnings Forecast for TG Therapeutics Issued By B. Riley

Key Points

• B. Riley has reduced its Q3 2025 earnings per share estimate for TG Therapeutics from $0.40 to $0.27, with a current consensus full-year earnings estimate of $0.08 per share.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a target price of $37.00, while the average rating for the stock is classified as a "Moderate Buy" with a consensus price target of $43.80.
• TG Therapeutics reported Q2 earnings of $0.17 per share, which fell short of the consensus estimate of $0.32, despite revenue increasing 92.1% year-over-year to $141.15 million.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Analysts at B. Riley dropped their Q3 2025 EPS estimates for TG Therapeutics in a report released on Monday, August 4th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of $0.27 per share for the quarter, down from their previous estimate of $0.40. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' FY2025 earnings at $0.88 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 27.83%. The business's quarterly revenue was up 92.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.04 earnings per share.

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $46.25.

TG Therapeutics Price Performance

TG Therapeutics stock traded down $1.18 during midday trading on Thursday, reaching $26.71. 4,790,083 shares of the stock were exchanged, compared to its average volume of 2,380,766. The company's fifty day moving average is $36.10 and its 200-day moving average is $35.95. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. The firm has a market cap of $4.24 billion, a PE ratio of 72.19 and a beta of 1.95. TG Therapeutics has a 52 week low of $19.45 and a 52 week high of $46.48.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ameritas Advisory Services LLC purchased a new position in shares of TG Therapeutics in the second quarter worth $25,000. Vermillion Wealth Management Inc. bought a new stake in TG Therapeutics in the fourth quarter worth $30,000. NBC Securities Inc. increased its position in TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 823 shares during the last quarter. Golden State Wealth Management LLC increased its position in TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 433 shares during the last quarter. Finally, SVB Wealth LLC bought a new stake in TG Therapeutics in the first quarter worth $37,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares in the company, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.64% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.